Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Post by bligickaon Oct 07, 2020 2:15am
235 Views
Post# 31678706

Pfizer, BioNTech Start Approval Process For Covid-19 Vaccine

Pfizer, BioNTech Start Approval Process For Covid-19 VaccinePfizer, BioNTech Start Approval Process For Covid-19 Vaccine Candidate In Europe...... Pfizer(PFE) andBioNTech(BNTX) announced early Tuesday that they've started a "rolling submission" for the approval of their Covid-19 vaccine candidate with the European Medicines Agency. BNTX stock rose early, but PFE fell after edging higher.....The partners are in Phase 3, or final-phase, testing of their vaccine candidate. Pfizer has said initial Phase 3 clinical trial results could be in by the end of October. In their news release, the two companies said they'll work with the EMA's Committee for Medicinal Products for Human Use, or CHMP, to complete the rolling review process to facilitate the final Marketing Authorization Application.
<< Previous
Bullboard Posts
Next >>